Clinical Trials Logo

Hypercholesterolemia clinical trials

View clinical trials related to Hypercholesterolemia.

Filter by:

NCT ID: NCT00269217 Completed - Clinical trials for Primary Hypercholesterolemia

Lipid Efficacy Study (0524B-022)(COMPLETED)

Start date: January 2006
Phase: Phase 3
Study type: Interventional

This is a 12-week clinical trial in patients with primary hypercholesterolemia or mixed hyperlipidemia, studying the effects of coadministered MK0524B on lipids. There will be 6 scheduled clinic visits, and 7 treatment arms.

NCT ID: NCT00269204 Completed - Clinical trials for Primary Hypercholesterolaemia

Lipid Efficacy/Tolerability Study (0524A-020)

Start date: December 2005
Phase: Phase 3
Study type: Interventional

A 28-week clinical trial in patients with primary hypercholesterolemia or mixed hyperlipidemia to study the effects of MK0524A on lipids and tolerability. There will be 9 scheduled clinic visits, and 3 treatment groups. A patient can be randomly assigned to 1 of the 3 treatment groups.

NCT ID: NCT00268697 Completed - Clinical trials for Hypercholesterolemia

Efficacy of Lapaquistat Acetate Alone and With Ezetimibe in Subjects With Primary Dyslipidemia.

Start date: October 2005
Phase: Phase 3
Study type: Interventional

The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), taken with ezetimibe on cholesterol levels in subjects with primary dyslipidemia

NCT ID: NCT00267254 Completed - Clinical trials for Hypercholesterolemia

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.

Start date: January 2006
Phase: Phase 3
Study type: Interventional

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of cholesterol medications to see how the different treatments compare to one another.

NCT ID: NCT00257686 Completed - Clinical trials for Hypercholesterolemia or Combined Dyslipidemia

Study to Compare the Efficacy and Safety of Pitavastatin and Pravastatin in Elderly Patients

Start date: September 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of pitavastatin with that of pravastatin in elderly patients

NCT ID: NCT00256516 Completed - Clinical trials for Cardiovascular Diseases

Low Carbohydrate Portfolio or "Eco-Atkins" Diet

Start date: April 2005
Phase: Phase 2
Study type: Interventional

Exchange of the butter, eggs, cheese and meat in the Atkins diet for soy protein foods, other vegetable proteins including gluten and vegetable fats, nuts, avocado, olive and canola oil will result in dramatic rather than modest reductions in blood lipids with weight loss. In effect this will represent an exchange of saturated fat and animal protein for healthy monounsaturated and polyunsaturated fats and vegetable proteins with significant effects on blood lipids while still encouraging weight loss.

NCT ID: NCT00256178 Completed - Clinical trials for Hypercholesterolemia

Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.

Start date: October 2005
Phase: Phase 3
Study type: Interventional

The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), taken with simvastatin on cholesterol levels in subjects with primary dyslipidemia

NCT ID: NCT00255216 Completed - Hyperlipidemia Clinical Trials

Policosanol for the Treatment of Hypercholesterolemia

Start date: January 2005
Phase: N/A
Study type: Interventional

Policosanol, a compound derived from sugar cane wax and available in health food stores across the United States, is a popular non-prescription product for treating hypercholesterolemia. Virtually all of the published medical literature on policosanol has been authored by research groups in Cuba. This study will assess the short-term safety and efficacy of policosanol in healthy adults who have a baseline LDL-C of 130-200. The recruitment population will be derived from primary care clinics consisting primarily of Caucasian and African-American patients. The primary outcome measurements will be the percentage change in LDL-C. Secondary outcomes will include changes in total cholesterol, HDL-C, triglycerides, C-reactive protein, and lipoprotein sub-particles. This will be the first known randomized clinical trial of policosanol in North America. The data derived from this pilot study regarding the lipid lowering effects of policosanol will be used to support applications for further funding through institutions outside the Carolinas Healthcare System including the National Institute of Health (NIH). Specific Aim: To independently corroborate the lipid lowering effects of policosanol in a small pilot study.

NCT ID: NCT00254475 Completed - Clinical trials for Hypercholesterolemia

A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia

Start date: November 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to provide data on the dose response of simvastatin in lowering LDL-C when it is co-administered with valsartan in patients with both essential hypertension and hypercholesterolemia. The primary objective of the study will be to show that the combination of valsartan 160mg/simvastatin 40mg has superior efficacy compared to the combination of valsartan 160mg/simvastatin 20mg in percentage change from baseline in LDL-C.

NCT ID: NCT00252018 Completed - Hypertension Clinical Trials

The Effect of Broccoli Sprouts as a Nutritional Supplement in the Prevention of Cardiovascular Disease

Start date: January 2006
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate whether a daily intake of dried broccoli sprouts will improve the endothelial function of the participants as measured by Flow mediated dilation (FMD) The dried sprouts are chosen because broccoli sprouts are known as containing large amounts af the glucosinolate glucoraphanin which in vitro and in animal models has been shown to have a positive effect on the endothelium as measured by NO release.